Validation data presented at the 2025 Alzheimer’s & Parkinson’s Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater separation with Alzheimer’s pTau217 pathology than the benchmark Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) 

BELFAST, Northern Ireland, April 4, 2025 /PRNewswire/ — Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data and AI, presented NeuLogiq® Platform validation data for two novel assessments of cognitive impairment in Alzheimer’s dementia (AD), and proof-of-concept data in amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD) at the AD/PD™ 2025 in Vienna, Austria.

“We are excited to share data validating NeuLogiq Platform cognitive tasks to measure memory, executive function and psychomotor function in broader neurodegenerative indications. We also demonstrated sensitivity to underlying Alzheimer’s pathology, correlating to plasma ptau217 status,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “Additionally, our CNS-101 study demonstrated that patients could achieve high levels of adherence performing repeated cognitive and EEG tests at home to capture high quality data, making them suitable for use in clinical trials where precise measurement at the individual level is critical. Separately, data presented from our CNS-102 study provides proof-of-concept that NeuLogiq can capture data relevant in ALS-FTD, including patients with profound motor impairments. Collectively, these data confirm that the NeuLogiq Platform has the potential to enable earlier detection of disease and provide biopharma with longitudinal real-world data that can streamline clinical studies.” 

The first poster, titled “Neuropsychological phenotyping of Alzheimer’s dementia at home, using the Cumulus NeuLogiq Platform with plasma biomarkers,” featured data demonstrating that patients are willing and able to perform repeated cognitive and EEG testing at home, and the NeuLogiq Platform endpoints show greater separation with AD pathology (pTau217) than the benchmark endpoint (ADAS-Cog) throughout the study. Importantly, these endpoints accord with standard benchmarks and demonstrate patterns of patient impairment consistent with the literature. EEG biomarkers, including passive and task-based measures, demonstrate morphology and group differences as expected based on the literature.

The second poster titled, “Neurocognitive evaluation from the home: validation of the Cumulus Platform in FTD and ALS populations,” provided initial evidence that the NeuLogiq Platform can capture speech fluency and emotion recognition decline in patients living with ALS, offering potential utility as a digital biomarker of cognitive decline, in addition to providing proof-of-concept that the platform can capture meaningful neuropsychological data, relevant to the heterogeneity of the ALS-FTD phenotype.

Cumulus continues to advance the NeuLogiq Platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit www.cumulusneuro.com. 

About Alzheimer’s Disease and pTau217
Alzheimer’s is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, mood swings, changes in behavior and personality, and difficulty with language and communication. Currently, there is no known cure for Alzheimer’s. Today, earlier diagnosis can enable patients to make lifestyle changes, including exercising and decreasing alcohol consumption, both of which have been shown to slow disease progression. In the future, having the ability to diagnose patients earlier may expedite enrollment in clinical studies and the identification of new treatments. 

pTau217, a phosphorylated fragment of the tau protein, is a promising blood-based biomarker for detecting Alzheimer’s disease (AD) pathology, showing high accuracy in identifying amyloid and tau pathology, and potentially distinguishing AD from other neurodegenerative disorders.

About Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) 
ALS and FTD are two neurodegenerative diseases that share some similarities but also have distinct characteristics. ALS, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to the loss of motor neuron function and eventually causing muscle weakness and paralysis. FTD involves the progressive degeneration of neurons in the areas of the brain behind the forehead (the frontal lobe) and behind the ears (the temporal lobes), leading to changes in personality, behavior, and language. 

About Cumulus Neuroscience 
Our mission is to generate the data and insights required to accelerate the diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world. At Cumulus Neuroscience, we are advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform designed with 10 of the world’s leading pharma companies. This novel platform provides the critical data and insights needed for faster, more robust and cost-effective decision-making in clinical trials and patient care. NeuLogiq enables study sponsors to capture large amounts of real-world clinical data repeatedly over time, across multiple behavioral and physiological domains, in the clinic and at home. Together with machine learning (ML) analytics, Cumulus simplifies and improves the robustness of CNS clinical trials, providing objective assessment of study inclusion and treatment outcomes.

FOR MORE INFORMATION
Tina Sampath
tina.sampath@cumulusneuro.com 
Tel: 415.694.1175

Logo: https://mma.prnewswire.com/media/2657658/Cumulus_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/cumulus-neuroscience-presents-data-at-adpd-2025-annual-meeting-302420326.html

VICTORIA, Seychelles, April 4, 2025 /PRNewswire/ — KuCoin, a leading global cryptocurrency exchange, has successfully completed its SOC 2 Type II audit, marking a significant achievement in its commitment to the highest security and compliance standards. The audit demonstrates the exchange’s unwavering dedication to security, availability, confidentiality, privacy, and processing integrity.

SOC 2 is an internationally recognized auditing standard that evaluates how well companies safeguard customer data and ensure system reliability through rigorous internal controls. The Type II certification specifically focuses on the effectiveness of a company’s internal controls over a defined period.

The comprehensive audit, conducted over the course of a year by Decrypt Compliance, assessed KuCoin’s policies, procedures, and systems to ensure they align with industry-standard Trust Services Criteria. The independent review confirmed that KuCoin’s security practices are robust and reliable.

BC Wong, CEO of KuCoin, commented on the achievement, stating, “Attaining the SOC 2 certification underscores our dedication to implementing robust security measures and operational controls. This is also a solid step in our compliance strategy, from mandatory KYC for all users, to actively obtaining and applying for compliance certifications in multiple countries, including the MiCAR license, to now securing the SOC 2 certificate. Every step is a milestone in our journey to build a secure, transparent, and trusted platform.”

This certification is not only a reflection of KuCoin’s operational excellence but also a promise to its global community of over 40 million users. The exchange continues to strengthen its security protocols, enhance transparency, and ensure a resilient trading environment where both seasoned traders and newcomers can engage with confidence.

Looking forward, KuCoin plans to further bolster its security measures, invest in cutting-edge technologies, and maintain an open line of communication with its users regarding security practices and operational improvements. The exchange remains focused on building an inclusive platform for the global crypto community, where users can confidently trade and invest in digital assets.

For more information about KuCoin’s security commitment and future initiatives, visit KuCoin Security. 

About KuCoin

Founded in 2017, KuCoin is one of the pioneering and most globally recognized technology platforms supporting digital economies, built on a robust foundation of cutting-edge blockchain infrastructure, liquidity solutions, and exceptional user experience. With a connected user base exceeding 40 million worldwide, KuCoin offers comprehensive digital asset solutions across wallets, trading, wealth management, payments, research, ventures, and AI-powered bots.

KuCoin has garnered accolades such as “Best Crypto Apps & Exchanges” by Forbes and has been recognized among the “Top 50 Global Unicorns” by Hurun in 2024. This recognition reflects its commitment to user-centric principles and core values, which include integrity, accountability, collaboration, and a relentless pursuit of excellence. Learn more: https://www.kucoin.com/.

Photo – https://mma.prnewswire.com/media/2657500/EN_KuCoin_Achieves_SOC_2_Type_II_Certification_BLOG.jpg 
Logo – https://mma.prnewswire.com/media/2641815/KuCoin_Horizontal_Green_LOGO_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/kucoin-achieves-soc-2-type-ii-certification-strengthening-security-and-compliance-standards-302419868.html

Expands Global Reach with Official Amazon Launches Across Europe, the Middle East, and Australia

Flagship Products – Heartleaf Pore Control Cleansing Oil, Heartleaf Toner, and Niacinamide 10 + TXA 4 Serum – Top Their Amazon Categories

SEOUL, South Korea, April 4, 2025 /PRNewswire/ — The Founders, Inc., a global brand-building company, announced that its skincare brand Anua has officially launched on Amazon in Europe, the Middle East, and Australia, marking a significant step in its global expansion and reinforcing its position as a leading player in the fast-growing K-beauty market.

After achieving strong performance and growing brand recognition on Amazon US and Japan, Anua is building on that momentum with recent launches in the UK (January), Dubai (February), and now Germany and Australia. In addition to its success online, Anua is also available in leading brick-and-mortar retailers such as Ulta Beauty (US) and Boots (UK), further expanding its presence across key global markets. Through these official Amazon launches, Anua also aims to provide authentic products directly to customers, minimize confusion caused by unauthorized listings, and foster stronger trust in global markets.

Since entering these new markets, Anua’s signature products—Heartleaf Pore Control Cleansing Oil, Heartleaf 77 Soothing Toner, and Niacinamide 10 + TXA 4 Serum—have quickly climbed to the top of their respective categories, receiving an enthusiastic response from global consumers. In the UAE, the Cleansing Oil, Rice Enzyme Cleansing Powder and TXA Serum have claimed the top spot in their categories. The success of Ramadan and Spring Sale campaigns has further fueled Anua’s momentum, with additional products poised to become category bestsellers across the region.

A spokesperson from Anua commented, “This expansion marks a major milestone in our mission to become the number one global skincare brand representing K-beauty,” and added, “We’re committed to introducing new product lines, launching engaging promotions, and connecting with more customers worldwide through innovative products and thoughtful service.”

Since its launch in 2019, Anua has seen rapid growth—achieving over 200% year-on-year growth—and solidifying its place on the global skincare stage. The brand officially entered the US market in 2022, and in July 2023, saw a 537% sales increase during Amazon Prime Day. On Black Friday, Anua saw an 800% surge in daily sales, further establishing itself as a K-beauty frontrunner.

Brand Overview
Global Beauty Brand Anua
Founded in 2019, Anua is a skincare brand that carefully selects the most effective naturally derived and dermatological ingredients, offering a diverse range of products tailored to various skin concerns. Bestsellers include the Heartleaf 77 Soothing Toner, Heartleaf Pore Control Cleansing Oil, and Heartleaf 77 Clear Pad. The brand has seen impressive growth across major global platforms such as Amazon and eBay Japan, solidifying its status as one of K-beauty’s leading skincare brands.

Photo – https://mma.prnewswire.com/media/2653852/5_______5_1__1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/anua-launches-on-amazon-in-europe-the-middle-east-and-australia–accelerating-global-momentum-for-k-beauty-302415676.html